臨床整形外科51巻11号

2016年11月発行

誌上シンポジウム 骨粗鬆症診療—整形外科からの発信

骨粗鬆症マーカー

著者： 斎藤充¹ 丸毛啓史¹

所属機関： ¹東京慈恵会医科大学整形外科

ページ範囲：P.1017 - P.1025

　骨粗鬆症は骨強度が低下する疾患である．骨石灰化度と骨の微細構造は骨の新陳代謝機構である骨吸収と骨形成のバランスにより規定されるのに対して，骨の主要な骨性成分であるコラーゲンの強度は，骨芽細胞機能やコラーゲン周囲の環境(酸化ストレス，糖化ストレス)に依存する．前者は骨代謝マーカー(骨吸収，形成マーカー)を用いて評価することが可能であるが，後者は，コラーゲンの劣化物質である終末糖化産物(ペントシジン，カルボキシメチルリジン)や，劣化の原因となる生活習慣病関連因子(ホモシステイン，HbA1cなど)を測定することにより評価する．

参考文献

1) Saito M, Marumo K. Collagen cross-links as a determinant of bone quality:a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int (Review) 2010;21:195-214.

2) Saito M, Marumo K. Effects of collagen crosslinking on bone material properties in health and disease. Calcif Tissue Int (Review) 2015;97:242-61.

3) Ivaska KK, Gerdhem P, Väänänen HK, et al. Bone turnover markers and prediction of fracture:a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res 2010;25:393-403.

4) Gonnelli S, Cepollaro C, Pondrelli C, et al. Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int 1999;65:359-64.

5) 日本骨粗鬆学会骨代謝マーカー検討委員会(西澤良記，犬田博明，三浦雅一・他編)．骨粗鬆症診療における骨代謝マーカー適正使用ガイドライン(2012年版)．Osteoporosis Jpn 2012；20：31-55．

6) Nishizawa Y, Ohta H, Miura M, et al. Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab 2013;31:1-15.

7) Vasikaran S, Cooper C, Eastell R, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med 2011;49:1271-4.

8) Chavassieux P, Portero-Muzy N, Roux JP, et al. Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women? J Clin Endocrinol Metab 2015;100:4662-8.

9) Iseki K, Kinjo K, Iseki C, et al. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004;44:806-14.

10) 米本圭吾，斎藤　充，黒坂大三郎・他．両側人工膝関節置換術後に介達外力により両側同時に膝蓋骨骨折を生じた1症例．Bone Joint Nerve 2005；6：219-22．

11) Shiraki M, Kuroda T, Shiraki Y, et al. Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis under bisphosphonate treatment. J Bone Miner Metab 2011;29:62-70.

12) Shiraki M, Urano T, Kuroda T, et al. The synergistic effect of bone mineral density and Methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures. J Bone Miner Metab;26:595-602.

13) Saito M, Grynpas MD, Burr DB, et al. Treatment with eldecalcitol positively affects mineralization, microdamage, and collagen crosslinks in primate bone. Bone 2015;73:8-15.

14) Saito M, Marumo K, Kida Y, et al. Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1-34) for 18 months contribute to improvement of bone strength in ovariectomized monkeys. Osteoporos Int 2011;22:2373-83.

15) Saito M, Kida Y, Nishizawa T, et al. Effects of 18-month treatment with bazedoxifene on enzymatic immature and mature cross-links and non-enzymatic advanced glycation end products, mineralization, and trabecular microarchitecture of vertebra in ovariectomized monkeys. Bone 2015;81:573-80.

16) Saito M, Marumo K, Soshi S, et al. Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int 2010;21:655-66.

17) Saito M, Shiraishi A, Ito M, et al. Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone 2010;46:1170-9.

18) Saito M, Fujii K, Soshi S et al. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int 2006;17:986-95.

19) Saito M, Fujii K, Mori Y, et al. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in the spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006;17:1514-23.

20) Mitome J, Yamamoto H, Saito M, et al. Non-enzymatic crosslinking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients. Calcif Tissue Int 2011;88:521-9.

21) Allen MR, Newman CL, Chen N, et al. Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease. Osteoporos Int. 2015;26:977-85.

22) Saito M, Fujii K, Marumo K. Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 2006;79:160-8.

23) 斎藤　充，木田吉城，荒川翔太郎・他．慢性閉塞性肺疾患における骨脆弱化機序の解明．総合健診2013；40：587-92．

24) 種田雅仁，斎藤　充，中野貴由・他．糖尿病では骨コラーゲンのAGEs化と生体アパタイト結晶の配向性の低下が骨強度低下に関与する．2型糖尿病モデルを用いた検討．日整会誌2015；89：S1685．

25) Shinno Y, Ishimoto T, Saito M, et al. Comprehensive analyses of how tubule occlusion and advanced glycation end-products diminish strength of aged dentin. Sci Rep 2016;6:19849. doi:10.1038/srep19849.

26) Shiraki M, Kuroda T, Tanaka S, et al. Non-enzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures, J Bone Miner Metab 2008;26:93-100.

27) Shiraki M, Kuroda T, Shiraki Y, et al. Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis under bisphosphonate treatment. J Bone Miner Metab 2011;29:62-70.

28) Yamamoto M, Yamaguchi T, Yamauchi M, et al. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2007;93:1013-9.

29) Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009;94:2380-6.

30) Barzilay JI, Circulating levels of carboxy - methyl - lysine (CML) are associated with hip fracture risk:the Cardiovascular Health Study. J Bone Miner Res 2014;29:1061-6.

31) Takahashi M, Oikawa M, Nagano A. Effect of age and menopause on serum concentrations of pentosidine, an advanced glycation end product. J Gerontol A Biol Sci Med Sci 2000;55:M137-40.

32) 木田吉城，斎藤　充，曽雌　茂・他．非侵襲的骨質評価法の確立—皮膚AGEsリーダー・血/尿ペントシジンおよび測定値と骨AGEs量との相関性の検討．Osteoporosis Jpn 2010；18：25-8．

33) Nakano M, Kubota M, Owada S, et al. The pentosidine concentration in human blood specimens is affected by heating. Amino Acids 2013;44:1451-6.

34) Tanaka S, Kuroda T, Saito M, et al. Urinary pentosidine improves risk classification using fracture risk assessment tools for postmenopausal women. J Bone Miner Res 2011;26:2778-84.

35) 玉置淳子，伊木雅之，甲田勝康・他．男性骨粗鬆症コホート研究5年次追跡による骨折発生予知における終末糖化産物の細胞外受容体(esRAGE)およびesRAGE/ペントシジン比の測定意義の検討．Osteoporosis Jpn 2013；4：740-8．

36) 藤田裕規，伊木雅之，玉置淳子・他．終末糖化産物ペントシジンは日本人高齢男性の骨折予測因子と成り得る．藤原京スタディ男性骨粗鬆症(FORMEN)研究．Osteoporosis Jpn 2015；23：Suppl. 198．

37) Gineyts E, Munoz F, Bertholon C, et al. Urinary levels of pentosidine and risk of fracture in post-menopausal women:the OFELY study. Osteoporos Int 2010;21:243-50.

38) McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004;350:2042-9.

39) van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004;350:2033-41.

40) Leboff MS, Narweker R, LaCroix A, et al. Homocysteine levels and risk of hip fracture in postmenopausal women. J Clin Endocrinol Metab 2009;94:1207-13.

41) McLean RR, Hannan MT. B vitamins, homocysteine, and bone disease:epidemiology and pathophysiology. Curr Osteoporos Rep 2007;5:112-9. Review.

42) Yang J, Hu X, Zhang Q, et al. Homocysteine level and risk of fracture:A meta-analysis and systematic review. Bone 2012;51:376-82.

43) Kuroda T, Tanaka S, Saito M, et al. Plasma level of homocysteine associated with severity of vertebral fracture in postmenopausal women. Calcif Tissue Int 2013;93:269-75.

44) Nozaka K, Kimura Y, Miyakoshi N, et al. Incidence of osteoporotic fracture in patients with high plasma homocysteine. American Academy of Orthopaedic Surgeons, Final Program, Educational program 2012;p.212.

45) Abraham AC, Agarwalla A2, Yadavalli A, et al. Multiscale predictors of femoral neck in situ strength in aging women:Contributions of BMD, cortical prosity, reference point indentation, and nonenzymatic glycation. J Bone Miner Res 2015;30:2207-14.